Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference: What Investors Need to Know

Haemonetics Corporation (NYSE: HAE) has announced its participation in the upcoming Raymond James 46th Annual Institutional Investors Conference. Chris Simon, President and CEO, will engage in a fireside chat with investors on Tuesday, March 4, 2025, at 2:50 p.m. ET. The event will be accessible to the public through a live webcast on Haemonetics' Investor Relations website and via a dedicated link. Following the presentation, a replay will be made available approximately 12 hours after the event and will remain accessible for 90 days through the company's Investor Relations website.

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. The company operates primarily through three segments: plasma, blood center, and hospital. Its product portfolio includes automated blood component and manual whole blood collection systems, software solutions for blood centers, and hemostasis management products.



As an investor, you may be wondering what to expect from Haemonetics' presentation at the Raymond James conference. Here are some key aspects to focus on:

1. Financial Performance: Investors will likely be interested in Haemonetics' recent financial performance, including revenue growth, earnings per share (EPS), and profit margins. The company's latest earnings report, released on February 6, 2025, showed a trailing 12-month revenue of $1.37 billion and EPS of $2.54. Keep an eye on any updates or guidance provided during the presentation.
2. Product Pipeline: Haemonetics' product pipeline is a crucial aspect of its long-term growth prospects. The company may provide updates on its ongoing research and development efforts, as well as any new products or technologies in the pipeline. This information can help investors assess the company's competitive position and potential for future growth.
3. Strategic Initiatives: Haemonetics may discuss its strategic initiatives, such as acquisitions, partnerships, or expansion plans. These updates can provide insight into the company's long-term vision and its approach to capturing new market opportunities.
4. Market Trends and Opportunities: The presentation may also touch on market trends and opportunities in the blood management and healthcare sectors. Haemonetics' perspective on these trends can help investors understand the company's positioning and potential for growth in the coming years.
5. Analyst Ratings and Price Targets: As of February 25, 2025, the average price target for Haemonetics is $103.56, which is 64.33% higher than the current price. The consensus rating is "Strong Buy." Investors may be interested in any updates to these ratings or price targets following the presentation.



In conclusion, Haemonetics' presentation at the Raymond James 46th Annual Institutional Investors Conference is an opportunity for investors to gain valuable insights into the company's financial performance, product pipeline, strategic initiatives, and market trends. By staying informed and engaged, investors can make more informed decisions about their investments in Haemonetics and the broader healthcare sector.